Skip to main content
Erschienen in: Cancer Causes & Control 5/2013

01.05.2013 | Original paper

Anthropometric factors in relation to risk of glioma

verfasst von: Rebecca B. Little, Melissa H. Madden, Reid C. Thompson, Jeffrey J. Olson, Renato V. LaRocca, Edward Pan, James E. Browning, Kathleen M. Egan, L. Burton Nabors

Erschienen in: Cancer Causes & Control | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Increased height and greater adiposity have been linked to an increased risk of many cancer types, though few large studies have examined these associations in glioma. We examined body weight and height as potential risk factors for glioma in a large US-based case–control study.

Methods

The analysis included 1,111 glioma cases and 1,096 community controls. In a structured interview, participants reported their height and weight at 21 years of age, lowest and highest weight in adulthood, and weight 1–5 years in the past.

Results

Being underweight at age 21 (BMI < 18.5 kg/m2) was inversely associated with the risk of glioma development. This protective association was observed in both men and women, but reached statistical significance in women only (multivariate OR 0.68; 95 % CI 0.48, 0.96). When BMI at age 21 was assessed as a continuous variate, a small but significant increase in risk was observed per unit increase in kg/m2 (OR 1.04; 95 % CI 1.02, 1.07). Adult height, recent body weight, and weight change in adulthood were not associated with glioma risk. All results were similar among never smokers and were consistent after stratifying by glioma subtype.

Conclusion

The present data suggest that a low body weight in early adulthood is associated with a reduced risk of glioma later in life. Results are consistent with previous studies in showing no material association of glioma risk with usual adult body weight. The present study does not support any association of adult stature with glioma risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat ACS (2012) American cancer society facts and figures 2012 ACS (2012) American cancer society facts and figures 2012
3.
Zurück zum Zitat CBTRUS (2012) Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2008 CBTRUS (2012) Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2008
4.
Zurück zum Zitat Braganza MZ, Kitahara CM, de Berrington GA, Inskip PD, Johnson KJ, Rajaraman P (2012) Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 14:1316–1324. doi:10.1093/neuonc/nos208 PubMedCrossRef Braganza MZ, Kitahara CM, de Berrington GA, Inskip PD, Johnson KJ, Rajaraman P (2012) Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 14:1316–1324. doi:10.​1093/​neuonc/​nos208 PubMedCrossRef
5.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348:1625–1638. doi:10.1056/NEJMoa021423 PubMedCrossRef Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348:1625–1638. doi:10.​1056/​NEJMoa021423 PubMedCrossRef
7.
9.
Zurück zum Zitat Gunnell D, Okasha M, Smith GD, Oliver SE, Sandhu J, Holly JM (2001) Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 23:313–342PubMedCrossRef Gunnell D, Okasha M, Smith GD, Oliver SE, Sandhu J, Holly JM (2001) Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 23:313–342PubMedCrossRef
12.
Zurück zum Zitat World Health Organization (1995) Physical status: the use and interpretation of anthropometry, report of the WHO expert committee World Health Organization (1995) Physical status: the use and interpretation of anthropometry, report of the WHO expert committee
13.
Zurück zum Zitat Gray L, Lee IM, Sesso HD, Batty GD (2012) Association of body mass index in early adulthood and middle age with future site-specific cancer mortality: the Harvard alumni health study. Ann Oncol 23:754–759. doi:10.1093/annonc/mdr270 PubMedCrossRef Gray L, Lee IM, Sesso HD, Batty GD (2012) Association of body mass index in early adulthood and middle age with future site-specific cancer mortality: the Harvard alumni health study. Ann Oncol 23:754–759. doi:10.​1093/​annonc/​mdr270 PubMedCrossRef
Metadaten
Titel
Anthropometric factors in relation to risk of glioma
verfasst von
Rebecca B. Little
Melissa H. Madden
Reid C. Thompson
Jeffrey J. Olson
Renato V. LaRocca
Edward Pan
James E. Browning
Kathleen M. Egan
L. Burton Nabors
Publikationsdatum
01.05.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0178-0

Weitere Artikel der Ausgabe 5/2013

Cancer Causes & Control 5/2013 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.